Corpus Intelligence IC Memo — SCOTT & WHITE HOSPITAL BRENHAM 2026-04-26 15:54 UTC
IC Memo — SCOTT & WHITE HOSPITAL BRENHAM
Investment Committee Memorandum | TX | 55 beds | Grade C | EBITDA uplift $908K
🛡️ Public data only — no PHI permitted on this instance.
Investment Committee Memorandum

SCOTT & WHITE HOSPITAL BRENHAM

CCN 450187 | WASHINGTON, TX | 55 beds | April 26, 2026
EBITDA BridgeData Room
C
Investability

1. Target Overview & Investment Thesis

SCOTT & WHITE HOSPITAL BRENHAM is a 55-bed suburban community hospital in WASHINGTON, TX with $12.3M in net patient revenue and a 1.0% operating margin. The hospital serves a payer mix of 35.3% Medicare, 2.9% Medicaid, and 61.8% commercial.

Thesis: Turnaround. Our ML models identify $908K in annual EBITDA improvement potential from RCM optimization across 5 levers, lifting margin from 1.0% to 8.4% (+739bps).

Net Revenue HCRIS$12.3M
Current EBITDA COMPUTED$123K
Operating Margin COMPUTED1.0%
Occupancy HCRIS24.0%
Revenue / Bed COMPUTED$224K
Net-to-Gross HCRIS22.6%
Distress Probability ML54.6%

2. Market Context & Competitive Position

583
TX Hospitals
-0.7%
State Median Margin
229
Comparable Hospitals

TX has 583 Medicare-certified hospitals with a median operating margin of -0.7%. The target's margin of 1.0% places it above the state median. Among 229 size-comparable peers (28-110 beds), the median margin is 0.2%. The target performs in line with or above peers.

3. RCM Performance Analysis — Comparable Hospitals

Comps selected by bed count (28-110), prioritizing same-state peers. 229 hospitals in the comp set.

HospitalStateBedsRevenueMargin
SCOTT & WHITE HOSPITAL BRENHAM (Target)TX55$12.3M1.0%
THE HEART HOSPITAL BAYLOR PLANTX109$464.6M25.7%
DECATUR COMMUNITY HOSPITALTX81$361.0M-15.5%
WISE HEALTH SYSTEM - PARKWAYTX36$361.0M-15.5%
CHILDRENS MEDICAL CENTER OF PLTX72$336.7M20.9%
BAYLOR HEART AND VASCULAR HOSPTX53$255.0M30.0%
TEXAS ORTHOPEDIC HOSPITATX42$237.8M46.3%
PRESBYTERIAN HOSP FLOWER MOUNDTX99$215.0M28.3%
LAKE GRANBURY MEDICAL CENTERTX53$181.6M38.5%

4. Predicted Improvement Opportunities

Improvement targets set at P75 of comparable peers with 60% gap closure assumption. Coefficients calibrated to published research bands. Total EBITDA uplift: $908K (739bps margin improvement).

LeverCurrentTargetEBITDA ImpactMarginRamp
Net Collection Rate93.5%97.0%$258K+210bp18mo
Cost to Collect4.5%2.5%$246K+200bp12mo
Denial Rate Reduction12.0%6.5%$245K+199bp12mo
A/R Days Reduction5200.0%3800.0%$150K+122bp9mo
Clean Claim Rate88.0%96.0%$10K+8bp6mo

5. EBITDA Bridge

Net Collection Rate
$258K
Cost to Collect
$246K
Denial Rate Reduction
$245K
A/R Days Reduction
$150K
Clean Claim Rate
$10K
Total EBITDA Uplift$908K
Current EBITDA$123K
+ RCM Uplift+$908K
Pro Forma EBITDA$1.0M
Current Margin1.0%
Pro Forma Margin8.4%
WC Released (1x)$472K

6. Returns Analysis — Scenario Matrix

5-year hold, 5.5x leverage, 3% organic growth, 10%/yr debt paydown. Base case uses 100% of predicted RCM uplift. Bull case: 130% uplift at lower entry. Bear case: 50% uplift at higher entry.

ScenarioEntryExitEquity InEquity OutMOICIRR
Base Case10.0x10.0x$188K$9.9M52.48x120.8%
Base (11x exit)10.0x11.0x$188K$10.9M58.05x125.3%
Bull Case9.0x11.0x$170K$14.0M82.53x141.7%
Bull (12x exit)9.0x12.0x$170K$15.3M90.33x146.1%
Bear Case11.0x10.0x$207K$5.3M25.51x91.1%
Bear (11x exit)11.0x11.0x$207K$5.9M28.38x95.3%

7. Key Risks & Mitigants

SeverityRisk FactorMitigant
MediumLow occupancyAt 24.0%, fixed costs are spread over fewer patient days. Mitigant: volume growth is an additional upside lever not modeled in base case
HighElevated distress probabilityModel estimates 54.6% probability of financial distress. Mitigant: distressed entry pricing (7-9x) compensates for risk

8. Data Sources & Methodology Appendix

Data Sources

  • CMS HCRIS Cost Reports (Medicare-certified hospitals)
  • CMS Medicare Utilization (DRG-level volumes)
  • CMS Chronic Conditions (county-level disease prevalence)
  • HCRIS multi-year trend data (financial time series)

Comparable Selection

  • 229 hospitals with 28-110 beds
  • Same-state prioritization (n=230)
  • Comp margins: P25=-14.1% / P50=0.2% / P75=11.9%

Bridge Methodology

  • Targets: P75 of comparable peers (60% gap closure)
  • Denial: avoidable share = 35% of delta × NPR
  • AR: bad debt coefficient = $0.65 per day per $1K NPR
  • NCR: 60% coefficient on collection rate improvement
  • CDI: 0.75% of Medicare revenue per 0.01 CMI point

Returns Assumptions

  • Leverage: 5.5x entry (84.6% debt / 15.4% equity)
  • Organic growth: 3% annual EBITDA growth
  • Debt paydown: 10% of principal per year
  • Hold period: 5 years

Generated by SeekingChartis on April 26, 2026. All predictions use public data only. Confidence intervals calibrated via split conformal prediction (90% coverage target). This memo is for informational purposes and does not constitute investment advice.